Metabolic and Vascular Effects of Statins in Untreated Dyslipidemic Diabetic Patients
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
Type 2 diabetes (T2D), because of impaired glucose regulation and consequent hyperglycemia,
promotes the development of coronary heart disease. Secondary dyslipidemia is often
associated with T2D and enhances the risk of cardiovascular complications. HMG-CoA reductase
inhibitors (statins) are selectively administrated for the treatment of dyslipidemia, leading
to a significant reduction of cardiovascular risk. More recently, revisions to guidelines
have established a lower therapeutic LDL cholesterol goal for diabetic patients, requiring
the administration of higher dose of statin. However, it is unclear whether high dose statin
therapy could affect glycemic control in diabetic patients. Moreover, data regarding the
effects of statins on insulin-resistance and endothelial function are controversial.